A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This study will be a phase-1, open-label, placebo-controlled, evaluation of two-dosages of a
live, recombinant Newcastle disease virus expressing the spike protein of SARS-CoV-2
(NDV-HXP-S), an investigational product for IN, IM, or a combined IN+IM vaccination in
healthy adults previously immunized against COVID-19. The IN and IM live virus vaccinations
will be identical in composition and only differ in route of administration.